EN
icon
CN
CN | EN
Our Science
EpimAb's Proprietary Bispecific Platform : FIT-Ig®
Similar manufacturing convenience to monoclonal antibodies
Solubility comparable to monoclonal antibodies
Widely applicable to
multiple targets
Preserve the functions and properties of the monoclonal antibody
Tissue penetration
similar to monoclonal
antibodies
Production convenience
similar to monoclonal
antibodies
Pipeline
We have a robust and sustainable pipeline with 3 clinical stage assets (EMB-01, EMB-02 and EMB-06) and more than 10 preclinical stage candidates. Our proprietary FIT-Ig® platform and other technical capabilities enable us to target three strategic oncology areas (tumor targeting, dual checkpoint inhibitors, immune cell engagers) and maintain our strong momentum to advance additional preclinical assets to the clinic.
EMB-02
Preclinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
EMB-01
EMB-01 is a bispecific antibody based on EpimAb’s proprietary platform FIT-Ig® that has shown efficacy in multiple preclinical cancer models. It targets the Epidermal Growth Factor Receptor (EGFR) as well as the Hepatocyte Growth Factor Receptor (cMET). Currently, a global Phase I/II study is ongoing with sites open in China and the US.
EGFR/cMET
EMB-02
EMB-02 is a bispecific antibody targeting human programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) and is being evaluated in advanced solid tumors. This antibody is designed to target human PD-1 and LAG-3 concomitantly or independently and disrupt the immune suppression mediated by both pathways, thereby restoring T-cell effector function and enhancing anti-cancer activity. Currently, a global Phase I/II study is ongoing with sites opened in US and Australia.
PD-1/LAG-3
EMB-06
EMB-06 is a recombinant humanized bispecific antibody targeted against B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3). Upon binding to BCMA on tumor cell surface, EMB-06 can recruit and activate CD3 expressing T lymphocytes, thereby mediating the killing effect of T lymphocytes on tumor cells. Currently, a global Phase I/II study is enrolling patients in Australia.
BCMA/CD3
EMB-09
EMB-09 is a humanized bispecific antibody targeting immune checkpoints, and is designed to boost T cell anti-cancer activity. Preclinical results support further clinical investigation of EMB-09 in advanced solid tumors. IND enabling work is currently ongoing.
undisclosed
EMB-07
EMB-07 is a T cell redirecting bispecific antibody by targeting a novel tumor associated antigen (TAA) and cluster of differentiation 3 (CD3). EMB-07 is designed based on EpimAb’s proprietary bispecific antibody platform. Upon binding to TAA on the tumor cell surface, EMB-07 can recruit and activate CD3 expressing T lymphocytes, thereby promoting the cytotoxic effect of T lymphocytes. EMB-07 showed a promising preclinical efficacy and safety profile. IND submission is expected in 2022.
TAA/CD3
News
2021-07-07
EpimAb Biotherapeutics Provides Clinical Update for EMB-02 and EMB-06
2021-05-28
EpimAb Biotherapeutics CEO Dr. Chengbin Wu talks with BioCentury: "New path for a bispecific road less traveled"
2021-05-27
EpimAb Biotherapeutics Appoints Jerry Su, Ph.D. as Chief Technology Officer
Who We Are
EpimAb Biotherapeutics is a clinical stage biopharmaceutical company with research and manufacturing facilities in Shanghai and Suzhou. With our unique and proprietary platform technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that is able to generate bispecific molecules with antibody-like properties, we are creating a pipeline of novel therapeutics focused around immuno-oncology and other disease areas with high unmet need.
Contact
Shanghai
Adress
6th Floor, Building 2, Jinchuang Building, 702 Zhongke Road, Zhangjiang High-tech Park, Shanghai, 201204, China
Email
contact@epimab.com
Suzhou
Adress
Building 19, No.218 Sangtian Street, Suzhou Industrial Park 215128, China
Email
contact@epimab.com
shanghai
suzhou